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Abstract
Objective Patient-reported outcomes are important for clin-
ical practice and research, and should reflect what patients
perceive as important. The objective of this study was to
develop and preliminarily validate a brief, patient-derived,
disease-specific tool, the pancreatic cancer disease impact
(PACADI) score.
Methods The development was performed in two phases.
Forty-one patients with confirmed pancreatic cancer (PC)
selected dimensions of health related to the impact of the
disease. A weighting of the eight most frequently reported
dimensions was performed in a second sample of 80 PC
patients who also rated the impact on eight numeric rating
scales (NRS, range 0 to 10). The relative weights and the
scores from the NRS were used to compute the PACADI
score (range 0 to 10). The patients also completed Edmon-
ton Symptom Assessment System (ESAS) and EQ-5D.
Results Dimensions reported by more than 20 % of the
patients were included in the PACADI score (relative
weights in parenthesis): pain/discomfort (0.16), fatigue
(0.16), anxiety (0.15), bowel/digestive problems (0.14), loss
of appetite (0.13), dry mouth (0.11), itchiness (0.08), and
nausea (0.07). The PACADI score in the 80 PC patients had
a mean (SD) value of 3.26 (2.06) (95 % CI 2.80, 3.71), was
moderately to strongly correlated to ESAS sense of well-
being (r=0.69) and EQ-5D (r=−0.52), and discriminated
significantly between patients with and without PC.
Conclusion The PACADI score is a new eight-item, patient-
derived, disease-specific measure. Preliminary validation
regarding construct validity and discrimination encourages
further validation in independent patient samples.
Keywords Pancreatic cancer . Patient-reported outcomes .
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Introduction
Pancreatic cancer (PC) is the seventh most frequent cause of
cancer deaths worldwide [1, 2]. Data published from the
International Agency for Research on Cancer suggest that
the mortality rate is 96 % of the incidence rate [3]. The short
time from diagnosis to death in most patients makes re-
search challenging due to limited disease-specific follow-
up before transition into a general palliative stage. Frequent-
ly used outcomes in clinical and epidemiological research
include survival, assessment of pancreatic tumors and me-
tastases, soluble biomarkers, symptoms, function, and
health-related quality of life. PC presents with symptoms
that are most inflicting to patients. Thus, there is a need to
measure, document, and monitor the level of health status in
dimensions of high relevance and importance to patients in a
feasible manner.
Patient-reported outcomes (PROs) have become increasing-
ly emphasized in both clinical research and practice over the
last decades and include generic and disease-specific measures
[4, 5], as well as tools to measure utilities [6]. The Food and
Drug Administration (FDA) and the European Medicines
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Agency recommend that pharmaceutical industry researchers
provide sufficient evidence supporting benefit on PROs before
granting approval of a new therapeutic agent [7, 8].
The use of PROs is based on the idea that the patient is
the best source of information about the experience of their
own condition. This is particularly important when the pri-
mary goal is to improve health-related quality of life [9].
However, there are some general concerns related to the
feasibility of PROs. The questionnaires are often extensive
which may limit the number of patients who provide their
response, especially for longitudinal follow-up [10]. The
lack of relevance of items to patients may also negatively
influence the respondent rates.
The implication is that patients also are the best source of
information to identify the questions of importance and how
they should be presented. In rheumatology, the Rheumatoid
Arthritis Impact of Disease (RAID) score, based on patients’
selection of dimensions where the disease has the most
important impact, has been developed and validated [11,
12]. The RAID score has also been used to identify cut
points for acceptable symptom state, as perceived by
patients [13], as well as evaluating onset of response to
medication [14].
A number of self-reported measures have been used
in research in patients with PC, but until now, only the
European Organisation for Research and Treatment in
Cancer (EORTC) has developed a disease-specific in-
strument for PC [5]. The Quality of Life module for
pancreatic cancer (EORTC QLQ-PAN26) has 26 ques-
tions and is meant for use in conjunction with the
EORTC Quality of Life Questionnaire-C30 (EORTC C-
30) which is generic for patients with malignant disease.
Eventually, there are 56 questions to complete, which
limits the feasibility of the instrument both in research
and clinical practice, especially in patients with a severe
disease [10].
The NIH PROMIS initiative [15] includes a number of
items with multiple follow-up questions, which provide
detailed and relevant information. Each question has Likert
scale response options. PROMIS is a dynamic, promising
tool to measure health outcomes, but it has to our knowl-
edge not been validated in PC.
The objectives of this study were to develop a brief,
patient-derived, disease-specific tool—pancreatic cancer
disease impact (PACADI) score—and to perform a prelim-
inary validation.
Methods
The methods for this project were modeled after the RAID
score methodology but with some modifications based on
the differences between the diseases.
The RAID score
An international group of ten patients with rheumatoid
arthritis (RA) from ten countries was selected in the first
phase (17 dimensions) where the disease had important
impact. The second step was performed by 100 patients
from the same countries, who ranked the dimensions for
importance to reduce the number of dimensions to seven
[11].
In the second phase, 500 patients from the same countries
were asked to distribute 100 points between the 7 dimen-
sions. Weights were ranked within each individual, and the
average ranks were used for the final weight of each dimen-
sion. These ranks formed the basis for the final weights and
were linearly transformed to a 0–100 scale. These weights
were multiplied by the results of the numeric rating scales
(NRS) and added together into the RAID score with a range
from 0 to 10 [12].
An international multicentre cross-sectional and longitu-
dinal study of consecutive RA patients from 12 European
countries was conducted in the third phase to examine the
psychometric properties of the combinations of instruments
that might be included within the RAID and the use of NRS
for each dimension. Construct validity was assessed cross-
sectionally.
The PACADI score
First phase: selection of dimensions and follow-up
examinations
Different from the patients with RA, who were familiar with
their disease, the patients with PC only recently faced a
severe disease at time of inclusion. For the PACADI score,
based on an ethical consideration, individual settings were
chosen to replace the group format. The study is a single
center study on a tertiary level.
The goal was to include 30 patients for the identification of
dimensions. There is no definitive answer to decide the sam-
ple size in qualitative approaches. However, the principle of
saturation, i.e., to reveal the full range of important percep-
tions, is regarded as an indicator. A critical review from
Yamazaki et al. found a median sample size of 36 [16]. The
first sample consisted of 52 consecutively referred patients
between November 2008 and July 2009 with symptoms and
findings indicating PC. After the diagnostic procedures, 41
had confirmed diagnoses of PC (ICD10 C25*) based on
cytology or histology in 92.7 % of the patients. Three patients
(7.3 %), in whom all clinical, biochemical, and radiological
data were consistent with pancreatic adenocarcinoma, were
included based on findings by imaging modalities. Demo-
graphic and disease characteristics at baseline of the 41
patients with confirmed PC are shown in Table 1 (for the
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entire enrolled population (n=52) see online supplementary
Table S1).
With a qualitative approach, the patients were asked an
open-ended question to identify up to 10 important dimen-
sions of health related to the impact of the disease. The
patients were shown a list of 56 dimensions (Table S2) from
frequently used and relevant generic and disease-specific
PRO instruments, and were then asked to report as free text
the most important dimensions according to their personal
opinion, but not in prioritized order. The selected dimen-
sions were given priority according to importance by the
patients immediately after selection, giving 1 to the most
important, 2 to the next, etc.
Age, gender, body weight, and height at baseline were
recorded. Body mass index (BMI) was computed. Regular
weight prior to disease onset was recorded, and weight loss
to baseline was calculated. Date of surgery was registered, if
performed.
The patients also completed Edmonton Symptom System
(ESAS) [4] and EuroQol-5D (EQ-5D) [6]. ESAS consists of
ten NRS (scales 0–10). The Norwegian ESAS version was
used with the following ten items: pain at rest, pain at
movement, fatigue, nausea, dyspnea, dry mouth, loss of
appetite, anxiety, depression, and sense of well-being [10].
EQ-5D is a five-item instrument that can be used in cost–
utility analyses. Three of the items concern physical func-
tion, and the two last items address anxiety and pain. Each
question has three response options (none/minor, moderate,
or major problem). A single score from zero to one can be
calculated.
We repeated the selection of important dimensions of
health, after 1 and 2 months in a longitudinal design, to
examine if the selection of important dimensions changed
during the disease course. Data were available in 29 out of
the 41 patients. Three patients died before the follow-ups
were completed. Three dropped out, and six were too weak
and died between 4 and 8 months after inclusion.
Second phase: weighting
Patients with PC (sample 2) were included between Sep-
tember 2009 and September 2011 based on the same inclu-
sion criteria as in sample 1. Out of the 110 patients with
suspected PC (online supplementary Table S1), 80 had
confirmed PC (Table 1). Selection of important dimensions
of health and data collection were similar to sample 1
(demographics, ESAS, and EQ-5D), but included one NRS
(scales 0–10) for each of the selected dimension of the
PACADI score (online supplementary Table S3, showing
the eight NRS in Norwegian and in English translation (see
Table S3 for description of the translation process)) [17].
Each NRS addressed the impact on each dimension during
the last week. The last week was chosen as a time frame for
overall impression of the health dimensions in the PACADI
score, since patients often report fluctuating severity of their
health problems. The 1-week time frame is similar to the
RAID score and different from the ESAS (same day). Time
frame varies between instruments, and 1 week has been
found as valid as momentary assessment [18].
For the weighting exercise, the following question was
asked: “Considering your entire disease duration, please
distribute 100 points among the following eight dimensions
of health based upon the impact of the disease on these
dimensions.” This methodology is identical to the method-
ology for assigning weights to the dimensions of the RAID
score [9] and as described by Ruta et al. [23].
Table 1 Demographic and disease characteristics at baseline for sam-
ple 1 for selection of dimensions and sample 2 for weighting and
preliminary validation
Sample 1 (n=41)a Sample 2 (n=80)a
Phase 1 Phase 2
Age (years) 68.3 (8.5) 66.7 (10.3)
Females 18 (43.9) 39 (48.8)
Weight 70.4 (13.4) 72.1 (13.1)
Weight lossb 7.2 (5.7) 7.8 (8.7)
BMI 23.0 (3.6) 24.2 (3.9)
Surgery 18 (43.9) 41 (51.9)
Stages of pancreatic cancer
Delimited 18 (43.9) 75 (68.2)
Locally advanced 12 (29.3) 24 (21.8)
Metastatic 11 (26.8) 11 (10.0)
Confirmation of PC diagnoses
Imaging modalities 3 (7.3) 8 (10.0)
Cytology 13 (31.7) 14 (17.5)
Histology 25 (61.0) 58 (72.5)
Health status measures
EQ-5D 0.61 (0.26) 0.60 (0.26)
ESAS
Pain at rest 3.00 (2.54) 2.19 (2.76)
Pain at movement 2.55 (2.16) 2.35 (2.84)
Fatigue 3.93 (2.46) 3.93 (3.01)
Nausea 1.65 (2.61) 1.36 (2.50)
Dyspnea 1.40 (2.18) 1.12 (2.00)
Dry mouth 2.78 (2.64) 2.86 (3.02)
Loss of appetite 3.78 (3.19) 3.26 (3.45)
Anxiety 3.35 (3.00) 3.17 (2.80)
Depression 3.43 (2.93) 2.57 (2.68)
Sense of well-being 3.93 (2.43) 3.75 (2.80)
Mean (SD) for continuous variables and numbers (%) for categorical
variables
a EQ-5D available in 40 patients in sample 1, and 49 in sample 2;
ESAS available in 40 patients in sample 1, and 69 in sample 2
bWeight loss from disease onset to baseline
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The weights of the PACADI profile were ranked from
8 to 1 in each patient (8 was given to the dimension with
highest weight). If two dimensions had identical weights,
they were given the same rank. The mean of the rank of
weights for each dimension was calculated and was then
normalized to a scale from 0 to 1 (i.e., the sum of all weights
was equal to 1.0). NRS were also used in the RAID score
and were performed, as well as other and more comprehen-
sive tools within the same dimension. In addition, NRS is
faster and more feasible to complete for patients than more
comprehensive questionnaires and visual analogue scales
[19]. The final step in computing the PACADI score was
to multiply the NRS values with the normalized final
weights and then to provide a sum of these products in each
individual patient.
Third phase: preliminary validation
The preliminary validation in sample 2 included a compar-
ison of the PACADI scores across gender, between patients
undergoing versus not undergoing surgery, between patients
with and without confirmed PC in sample 2, and to examine
correlations between the PACADI score and age, ESAS
items and EQ-5D.
Statistics
Parametric statistical methods were preferred since data
appeared normally distributed based on Q–Q plots, and
mean and median values were similar. Parametric meth-
ods were performed robustly [20] and were used in the
development of the RAID score. Demographic continu-
ous variables as well as PACADI score, ESAS and EQ-
5D are presented as mean (SD) values, and associations
between PACADI and continuous demographic variables,
ESAS and EQ-5D were examined with Pearson’s corre-
lation coefficient. Two-sample t tests were used for the
comparison of the PACADI score across dichotomized
variables. All analyses were performed in SPSS version
18. Two-tailed p values <0.05 were considered statisti-
cally significant.
Regulatory and ethical aspects
All data were stored with a numeric identifier in a separate,
secured research database detached from the identifier code
list. The code list was properly stored with accessibility for
the principal researchers only. The regional ethical commit-
tee approval of the protocol and patient information/consent
form was obtained separately for phases 1 and 2. The
privacy protection supervisor evaluated and accepted the
data-handling procedures. All participating patients signed
a written informed consent.
Results
Development of the PACADI score
First phase: selection of dimensions at baseline
and longitudinal assessment
Table 2 shows the number and percentage of patients in
sample 1, who at baseline, reported dimensions of health
where the disease had important impact. The right column in
Table 2 shows the single dimension of health that each of
the 41 patients regarded to have most important impact
(highest priority (number 1)). Dimensions reported less than
twice or not among the dimensions of highest impact (n=22
(50 %)) are not included in Table 2. With the aim of brevity,
the eight most frequently reported and highly prioritized
dimensions were selected for the PACADI profile. The
dimensions of health that were reported by more than
20 % of the patients were included as candidate dimensions
for the PACADI score: pain/discomfort (70.0 %), fatigue
(63.4 %), bowel and/or digestive problems (58.5 %), loss of
appetite (46.3 %), anxiety (39.0 %), dry mouth (31.7 %),
itchiness (24.4 %), and nausea (24.4 %) (Table 2).
The baseline analyses were repeated in the original sam-
ple of 52 referred patients (including 11 without PC) with
similar results (online supplementary Table S4). Pain/dis-
comfort, fatigue, bowel and/or digestive problems, and loss
of appetite were reported with stable importance. Anxiety
and itchiness were reported less frequently over time,
whereas the proportion reporting nausea increased (Fig. 1).
Second phase: weighting of the eight selected dimensions
and construction of the PACADI score
The mean weights attributed to each of the eight dimensions
are shown in Table 3. Pain/discomfort, fatigue, bowel and/or
digestive problems, and anxiety had the highest weights.
This table also shows the mean rank of the weights for each
dimension based on ranks from 8 to 1. The means of each of
these ranks were normalized to a scale from 0 to 1 to create
the final weights to be used in the PACADI score. The sum
of these normalized weights was 1.0 (Table 3).
The weights were examined in the 110 referred patients
with suspected PC in whom 30 had other diagnoses than PC
(see online supplementary Table S5). The weights in this
total sample were similar to the weights shown in Table 3.
The mean values of the reported NRS for the eight
dimensions are shown in Table 4. The PACADI score for
each patient was computed according to the following
formula (NRS values multiplied by the final weight):
pain/discomfort NRS×0.16+fatigue NRS×0.16+anxiety
NRS×0.15+bowel and/or digestive problems NRS×0.14+
loss of appetite NRS×0.13+dry mouth NRS×0.11+
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itchiness NRS×0.08+nausea NRS×0.07 (see also online
supplementary Table S2).
The mean (SD) baseline PACADI score in sample 2 was
3.26 (2.06) (95 % CI 2.80, 3.71, median 3.27, interquartile
range 3.45), whereas the mean of the scores from eight
NRSs without any weight was lower (3.07).
Third phase: preliminary validation
The PACADI score was similar in females and males (females/
males, n=39/41, mean (SD) 3.49 (2.05)/3.03 (2.06), p=0.32);
it did not correlate to age (r=0.09) and was not different in
patients undergoing versus not undergoing subsequent surgery
(no surgery/surgery, n=38/41 mean (SD) 3.62 (2.06)/2.86
(2.01), p=0.10). However, the PACADI score was significant-
ly higher in patients with confirmed PC (n=80) versus patients
with suspected but not confirmed PC (n=30) (mean difference
(95%CI) 0.80 (0.34, 1.56), p=0.04). ESAS appetite score was
also significantly worse in patients with versus without PC,
whereas the other ESAS items and EQ-5D did not discriminate
between the two patient groups.
Correlations between the PACADI score and EQ-5D and
ESAS were examined. The correlation coefficients varied
from 0.21 (dyspnea) to 0.72 (fatigue). Correlations to the
global measure of sense of well-being in ESAS and EQ-5D
were 0.69 (p<0.001) and −0.52 (p<0.001), respectively,
supporting that the PACADI has moderate to strong corre-
lations to other global measures (Table 5).
Discussion
The aim of this study was to develop a tool to facilitate a
seamless assessment and monitoring of PROs in patients
with PC in a research setting and in clinical practice. Clini-
cians have their perspective on collecting information for
decision making. The patient perspective is one out of four
key issues for decision making in evidence-based medicine
[21]. The PACADI score may help clinicians to identify and
monitor dimensions and symptoms that are highly relevant
Table 2 Number (percentage)
of patients with PC reporting
dimensions of health with im-
portant disease impact/most im-
portant impact (highest priority)
at baseline
Dimension Reported dimensions of health
with important disease impact
Reported dimensions of health
with most important disease
impact (highest priority)
N (% out of 41) N (% out of 41)
Pain/discomfort 29 (70.7) 13 (31.7)
Fatigue 26 (63.4) 1 (2.4)
Bowel and/or digestive problems 24 (58.5) 2 (4.9)
Loss of appetite 19 (46.3) 2 (4.9)
Anxiety 16 (39.0) 6 (16.6)
Dry mouth 13 (31.7)
Itchiness 10 (24.4) 5 (12.2)
Nausea 10 (24.4) 2 (4.9)
Weight loss 7 (17.1)
Diarrhea 6 (14.6)
Sleep problems 6 (14.6)
Depression 5 (12.2) 2 (4.9)
Eating habits 5 (12.2)
Family life 4 (9.8) 1 (2.4)
Dyspnea 4 (9.8)
Change in taste 3 (7.3)










Baseline Visit 2 Visit 3
Fig. 1 Percentage of patients (n=29) with PC reporting dimensions of
health with important disease impact at baseline and after 1 and
2 months
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to patients. The score is a global measure that has the
potential to be used in both clinical and research settings.
The decision to limit the inclusion of dimensions of
health that were reported by more than 20 % of the patients
as candidate items for the PACADI was based on the im-
portant goal to obtain a feasible score. This aspect is espe-
cially important in patients feeling unwell. The number of
dimensions was similar to the RAID score (eight versus
seven).
The idea behind the longitudinal assessment was to ex-
amine whether the selection of domains was stable over
time. Overall, the selection was stable but with a reduced
number of patients selecting anxiety and itchiness during
follow-up (Fig. 1). The reduced focus on anxiety may be
related to the adaptation to the disease after proper informa-
tion and that reduced reporting of itchiness may be
explained by procedures like stenting [22]. However, both
these dimensions remained in the PACADI score since they
obviously are important in the early phases of the disease,
which may be the phases of largest interest when consider-
ing current and future therapeutic options.
It was expected that some patients might have problems
understanding what was meant by dimensions of health.
Therefore, the probe list of 56 dimensions from frequently
used questionnaires (Table S2) was prepared and offered at
baseline to exemplify dimensions of health. About half of the
selected dimensions for PACADI were in the probe list; this
list was mostly used for the initial illustration of examples at a
glance. The use of this probe list could potentially have been a
limitation to the study by influencing the selection. During
follow-up, the probe list was available, but it was rarely used
by the patients. The selected dimensions were overall similar
at all three time points, even if the patients did not have access
to the previous selections (Fig. 1).
An alternative approach to the model of ranks of the
weights of each dimension could had been to use the mean
weights to construct the final weight (Table 3). However, the
weighting accentuates the patient perspective of importance.
The aim was to reach a number of patients, which was ten
times the number of dimensions [23]. Even so, only 80
patients from one single center is considered a limitation,
since the weighting procedure of the RAID score included
more than 500 patients across Europe. The intention for the
development of the PACADI instrument was to make it
disease-specific, and hence, only patients with PC were
included in the primary analyses. However, results were
similar both for selection of dimensions and weights when
both groups of patients were analyzed (Tables S1 and S4).
A particular strength of the PACADI score is that both
selection of dimensions (i.e., what to measure) and the
weighting procedure (i.e., how important is the dimension
Table 3 Results from the weighting exercise across the eight selected
dimensions of health in patients with PC (n=80). Mean (SD) weights,
mean (SD) ranks of the weights, and the mean ranks normalized to a







Pain/discomfort 17.8 (18.0) 4.5 (3.6) 0.16
Fatigue 14.4 (15.3) 4.7 (3.0) 0.16
Anxiety 17.0 (20.9) 4.2 (3.3) 0.15
Bowel and/or
digestive problems
13.8 (16.2) 4.0 (3.4) 0.14
Loss of appetite 12.7 (13.9) 3.8 (3.5) 0.13
Dry mouth 9.6 (15.2) 3.0 (3.0) 0.11
Itchiness 10.4 (19.8) 2.2 (3.2) 0.08
Nausea 5.1 (8.3) 2.0 (2.8) 0.07
aMean ranks divided by the sum of the mean ranks (28.4) (normaliza-
tion to a scale from 0 to 1)
Table 4 NRS and weighted NRS scores (NRS multiplied by the final
weight) within the proposed PACADI score dimensions
PACADI score dimensions Mean (SD) NRS Weighted NRSa
Pain/discomfort 3.25 (2.94) 0.52




Loss of appetite 3.34 (3.41) 0.43
Anxiety 3.67 (2.80) 0.55
Dry mouth 3.10 (2.95) 0.34
Itchiness 1.71 (2.81) 0.14
Nausea 1.81 (2.62) 0.13
Mean NRS score: 24.54/8=3.07
Sum of weighted NRS, i.e., PACADI score=3.26
aMean NRS value multiplied by the final weight (see Table 3)
Table 5 Associations between the PACADI score, EQ5D, and ESAS
items in patients with PC in sample 2 (n=80)
Pearson’s correlation coefficients p value
EQ-5Da −0.52 <0.001
ESASa
Pain at rest 0.54 <0.001




Dry mouth 0.48 <0.001
Loss of appetite 0.71 <0.001
Anxiety 0.29 0.03
Depression 0.47 <0.001
Sense of well-being 0.69 <0.001
a EQ-5D available in 49 patients; ESAS available in 69 patients
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to the patients) are based on the patients’ opinion. Inherent
in this design is the relevance of the tool to patients.
Several of NIH PROMIS items may be of relevance to
patients with pancreatic cancer. However, it seems that only
pain, fatigue, and anxiety are covered in both tools, since
PACADI reflects only the most important impact on health.
While PROMIS is measured on Likert scales, PACADI uses
NRS. NRS and Likert scales are often used interchangeably.
Likert scales seem to be more frequently used to measure
strength of agreement in attitude, whereas NRS seem to be
more frequently used for measuring severity/intensity, which
suits PACADI. Electronic versions of both tools would in-
crease both feasibility of completing and errors in datasets [24].
It seems that the three approaches related to the eight
selected dimensions of health (selection and giving priority
between dimensions of importance, weights, and symptom
severity) gave rather consistent results on a group level. For
example, the five dimensions reported as important by more
than 39% of the patients (pain/discomfort, fatigue, bowel and/
or digestive problems, loss of appetite, and anxiety; Table 1)
also had the highest weights (Table 3) and the worst scores on
NRS (Table 4). However, the data also indicated that patients
may differentiate between severity (the value on the NRS) and
the importance (the frequency of reporting dimensions of
importance to patients). Even if fatigue is reported as more
severe than pain/discomfort on NRS (Table 3), pain/discom-
fort is still the most important dimension to patients (Table 1).
This observation implies that asking patients “what is impor-
tant to you?” may give complimentary responses to asking
patients “how are you?” A similar differentiation between
severity and priority in patients with rheumatoid arthritis has
previously been reported [25].
In sample 2, the PACADI profile was tested (n=80) in a
preliminary validation. The moderate to strong correlations
to the global measure of well-being in ESAS and EQ-5D
supported that the PACADI score may perform as a global
PRO in patients with PC. Further, the weighted PACADI
score showed a slightly higher value than the mean of the
NRS profile (Table 4), which may support that the inclusion
of the weights may accentuate the patient perspective. In-
terestingly, the PACADI scores differentiated between
patients with and without confirmed PC, which may support
its role as a disease-specific tool, since a similar differenti-
ation was not seen for ESAS well-being and EQ-5D.
The PACADI score is a brief, patient-derived, disease-
specific measure. Preliminary validation regarding construct
validity and discrimination encourages further validation in
independent patient samples. It has the potential similar to
RAID [13, 14] to be used in both clinical and research
settings, but additional testing of reliability and a larger
scale validation in a population of at least 200 patients
according to requirements from the FDA [26] should be
performed. Sensitivity to change should be examined in
intervention studies, for example, by longitudinal compar-
isons of patients undergoing versus not undergoing surgery
[27]. It is also important that further validation is performed
in an international setting.
Acknowledgments Pathological examinations were performed by
I.M. Bowitz-Lothe MD, and A.M. Svardahl RN contributed to the data
collection. The authors have been funded by their institutions (shown
as affiliations in the author list).
Conflict of interest The authors have no conflicts of interest to
disclose.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and the source are credited.
References
1. Bosetti C, Bertuccio P, Negri E, La VC, Zeegers MP, Boffetta P
(2012) Pancreatic cancer: overview of descriptive epidemiology.
Mol Carcinog 51:3–13
2. Michaud DS (2004) Epidemiology of pancreatic cancer. Minerva
Chir 59:99–111
3. Pandol S, Gukovskaya A, Edderkaoui M, Dawson D, Eibl G,
Lugea A (2012) Epidemiology, risk factors, and the promotion of
pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol
27(Suppl 2):127–134
4. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The
Edmonton Symptom Assessment System (ESAS): a simple method
for the assessment of palliative care patients. J Palliat Care 7:6–9
5. Fitzsimmons D, Johnson CD, George S et al (1999) Development
of a disease specific quality of life (QoL) questionnaire module to
supplement the EORTC core cancer QoL questionnaire, the QLQ-
C30 in patients with pancreatic cancer. EORTC Study Group on
Quality of Life. Eur J Cancer 35:939–941
6. The EuroQol Group (1990) EuroQol—a new facility for the mea-
surement of health-related quality of life. Health Policy 16:199–208
7. Revicki DA, Gnanasakthy A, Weinfurt K (2007) Documenting the
rationale and psychometric characteristics of patient reported out-
comes for labeling and promotional claims: the PRO Evidence
Dossier. Qual Life Res 16:717–723
8. Cleeland CS, Sloan JA (2010) Assessing the Symptoms of Cancer
Using Patient-Reported Outcomes (ASCPRO): searching for
standards. J Pain Symptom Manage 39:1077–1085
9. Guyatt GH, Ferrans CE, Halyard MY et al (2007) Exploration of
the value of health-related quality-of-life information from clinical
research and into clinical practice. Mayo Clin Proc 82:1229–1239
10. Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH (2006)
Symptom profiles and palliative care in advanced pancreatic can-
cer: a prospective study. Support Care Cancer 14:1126–1133
11. Gossec L, Dougados M, Rincheval N et al (2009) Elaboration of
the preliminary Rheumatoid Arthritis Impact of Disease (RAID)
score: a EULAR initiative. Ann Rheum Dis 68:1680–1685
12. Gossec L, Paternotte S, Aanerud GJ et al (2011) Finalisation and
validation of the rheumatoid arthritis impact of disease score, a
patient-derived composite measure of impact of rheumatoid arthri-
tis: a EULAR initiative. Ann Rheum Dis 70:935–942
13. Dougados M, Brault Y, Logeart I, van der Heijde D, Gossec L,
Kvien T (2012) Defining cut-off values for disease activity states
and improvement scores for patient-reported outcomes: the
Support Care Cancer (2013) 21:1677–1684 1683
example of the Rheumatoid Arthritis Impact of Disease (RAID).
Arthritis Res Ther 14:R129
14. Dougados M, Ripert M, Hilliquin P, Brocq O, Brault Y, Logeart I
(2012) Onset of action of etanercept in rheumatoid arthritis based
on patient-reported outcomes. Clin Exp Rheumatol 30:266–268
15. Carle AC, Cella D, Cai L et al (2011) Advancing PROMIS’s
methodology: results of the Third Patient-Reported Outcomes
Measurement Information System (PROMIS®) Psychometric
Summit. Expert Rev Pharmacoecon Outcomes Res 11:677–684
16. Yamazaki H, Slingsby BT, Takahashi M, Hayashi Y, Sugimori H,
Nakayama T (2009) Characteristics of qualitative studies in influ-
ential journals of general medicine: a critical review. Biosci Trends
3:202–209
17. Guillemin F, Bombardier C, Beaton D (1993) Cross-cultural adap-
tation of health-related quality of life measures: literature review
and proposed guidelines. J Clin Epidemiol 46:1417–1432
18. Jamison RN, Raymond SA, Slawsby EA, McHugo GJ, Baird
JC (2006) Pain assessment in patients with low back pain:
comparison of weekly recall and momentary electronic data. J
Pain 7:192–199
19. Pincus T, Bergman M, Sokka T, Roth J, Swearingen C, Yazici Y
(2008) Visual analog scales in formats other than a 10 centimeter
horizontal line to assess pain and other clinical data. J Rheumatol
35:1550–1558
20. Fagerland MW, Sandvik L, Mowinckel P (2011) Parametric meth-
ods outperformed non-parametric methods in comparisons of dis-
crete numerical variables. BMC Med Res Methodol 11:44
21. Murad MH, Montori VM, Guyatt GH (2008) Incorporating patient
preferences in evidence-based medicine. JAMA 300:2483–2484
22. Larssen L, Medhus AW, Hjermstad MJ et al (2011) Patient-
reported outcomes in palliative gastrointestinal stenting: a Norwe-
gian multicenter study. Surg Endosc 25:3162–3169
23. Ruta DA, Garratt AM, Leng M, Russell IT, MacDonald LM (1994)
A new approach to the measurement of quality of life. The Patient-
Generated Index. Med Care 32:1109–1126
24. Heiberg T, Kvien TK, Dale O et al (2007) Daily health status
registration (patient diary) in patients with rheumatoid arthritis: a
comparison between personal digital assistant and paper-pencil
format. Arthritis Rheum 57:454–460
25. Heiberg T, Kvien TK (2002) Preferences for improved health
examined in 1,024 patients with rheumatoid arthritis: pain has
highest priority. Arthritis Rheum 47:391–397
26. FrostMH, Reeve BB, Liepa AM, Stauffer JW, Hays RD (2007)What
is sufficient evidence for the reliability and validity of patient-
reported outcome measures? Value Health 10(Suppl 2):S94–S105
27. Sonnenberg A, Rodriguez SA, Faigel DO (2008) Diagnostic as-
certainment of suspicious pancreatic mass: a threshold analysis.
Clin Gastroenterol Hepatol 6:1162–1166
1684 Support Care Cancer (2013) 21:1677–1684
